A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Running, not enrolling · Phase 3
Conditions studied: Advanced or Metastatic NRAS-mutant Melanoma
In brief
Stage 1: To select the optimal dose of naporafenib + trametinib to be studied in Stage 2. Stage 2: To compare progression free survival (PFS) and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + trametinib to that of patients who are randomized to physician's choice of therapy (dacarbazine, temozolomide, or trametinib monotherapy).
Key facts
- Study ID
- NCT06346067
- Run by
- Erasca, Inc.
- People needed
- 78
- Starts
- 2024-04-29
- Expected to finish
- 2028-12-01
- Last updated by the study team
- 2026-02-27
Who can join
Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of California, San Francisco — San Francisco, California, United States
- The Melanoma and Skin Care Institute — Englewood, Colorado, United States
- Mayo Clinic - Florida — Jacksonville, Florida, United States
- University of Miami Sylvester Cancer — Miami, Florida, United States
- University of Kansas Cancer Center — Kansas City, Kansas, United States
- Ochsner Clinic Foundation — Jefferson, Louisiana, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- Barbara Ann Karmanos Cancer Institute — Detroit, Michigan, United States
- Mayo Clinic — Rochester, Minnesota, United States
- Washington University School of Medicine — St Louis, Missouri, United States
- Memorial Sloan Kettering Cancer Center — New York, New York, United States
- Cleveland Clinic Foundation — Cleveland, Ohio, United States
- SCRI Oncology Partners (formerly Tennessee Oncology) — Nashville, Tennessee, United States
- Texas Oncology- Austin Midtown — Austin, Texas, United States
- Texas Oncology - Baylor Charles A. Sammons Cancer Center — Dallas, Texas, United States
- The University of Texas MD Anderson Cancer Center — Houston, Texas, United States
- The University of Utah - Huntsman Cancer Institute (HCI) — Salt Lake City, Utah, United States
- Virginia Oncology Associates — Norfolk, Virginia, United States
- Fred Hutchinson Cancer Center — Seattle, Washington, United States
- University of Wisconsin — Madison, Wisconsin, United States
- Calvary Mater Newcastle — Waratah, New South Wales, Australia
- Tasman Health Care — Southport, Queensland, Australia
- Princess Alexandra Hospital — Woolloongabba, Queensland, Australia
- Peter MacCallum Cancer Institute — Melbourne, Victoria, Australia
- Mayo Clinic - Arizona — Phoenix, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.